Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Asset Writedowns and Impairment (2020 - 2025)

NeuroPace has reported Asset Writedowns and Impairment over the past 6 years, most recently at $19000.0 for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at $19000.0 for Q4 2025, down 65.45% from a year ago — trailing twelve months through Dec 2025 was $159000.0 (down 36.65% YoY), and the annual figure for FY2025 was $159000.0, down 36.65%.
  • Asset Writedowns and Impairment for Q4 2025 was $19000.0 at NeuroPace, down from $47000.0 in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for NPCE hit a ceiling of $138000.0 in Q2 2021 and a floor of $19000.0 in Q4 2025.
  • Median Asset Writedowns and Impairment over the past 5 years was $47000.0 (2024), compared with a mean of $54750.0.
  • Biggest five-year swings in Asset Writedowns and Impairment: tumbled 92.2% in 2021 and later surged 241.67% in 2022.
  • NeuroPace's Asset Writedowns and Impairment stood at $57000.0 in 2021, then crashed by 31.58% to $39000.0 in 2022, then surged by 74.36% to $68000.0 in 2023, then decreased by 19.12% to $55000.0 in 2024, then plummeted by 65.45% to $19000.0 in 2025.
  • The last three reported values for Asset Writedowns and Impairment were $19000.0 (Q4 2025), $47000.0 (Q3 2025), and $49000.0 (Q2 2025) per Business Quant data.